Kancera AB (publ) (“Kancera”) today announces that the board has decided to initiate a process to seek potential stakeholders for a reverse take over of the company with the aim to materialize the value of its public listing. Kancera...
Read MoreThe period in brief – financial summary for the second quarter 2025 Net sales amounted to SEK 0 million (SEK 0 million). R&D expenses amounted to SEK 4,8 million (SEK 9,7 million). Operating loss for the quarter amounted to...
Read MoreKancera AB (publ) today announces that the company has terminated the letter of intent agreement with Recardio Inc. based on financing considerations. Kancera will now explore other out-licensing and business development opportunities.
Read MoreKancera AB (publ) (Kancera) announces that the World Health Organization has granted rugocrixan and fosrugocrixan as the International Non-proprietary Names for the company’s candidate drugs KAND567 and KAND145.
Read MoreKancera AB (publ) (Kancera) today reports the top-line results from the KANDOVA study, a one-arm, open-label, multi-centre combined phase Ib/IIa study of KAND567 in combination with carboplatin in ovarian cancer. The primary objective was met – to determine the...
Read More